Colorectal Cancer Stage IV Clinical Trial
Official title:
Calcium Electroporation for the Treatment of Colorectal Cancer
In this phase I study 6 patients with inoperable colorectal cancer is treated with calcium electroporation to establish safety and efficacy of the treatment.
A total of 6 evaluable patients with inoperable colorectal cancer are expected to be included in the study and the time for inclusion of patients is estimated to be 1-2 years. All patients will have been offered the standard of care and all available alternatives before entering the protocol. Calcium electroporation will not be compared to other means of treatment. All patients will be treated once, but in case of residual tumor tissue at follow-up, and if the investigator considers it safe, they will be offered re-treatment. A maximum of 3 treatments per patient will be conducted with an interval of minimum 4 weeks. The patients will be followed with regular examinations for 12 months, starting from first treatment day. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03594448 -
Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
|
||
| Completed |
NCT03986541 -
AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
|
||
| Completed |
NCT01570452 -
Matrilysin Expression in Different Stages of Colorectal Tumors
|
N/A | |
| Recruiting |
NCT05354817 -
Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin
|
Phase 2 | |
| Recruiting |
NCT05576896 -
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
|
Phase 2 | |
| Completed |
NCT04715061 -
Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments
|
N/A | |
| Terminated |
NCT03149679 -
The p53 Colorectal Cancer Trial
|
Phase 2 | |
| Completed |
NCT05550701 -
Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
|
||
| Enrolling by invitation |
NCT04149613 -
Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
|
||
| Completed |
NCT04425239 -
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT06329700 -
Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
|
||
| Recruiting |
NCT05382741 -
Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
|
Phase 2 | |
| Recruiting |
NCT06342440 -
Early Detection of Advanced Adenomas and Colorectal Cancer
|
||
| Not yet recruiting |
NCT04917276 -
Treatment Response Prediction System of mCRC Patients Based on CTC
|
||
| Not yet recruiting |
NCT06296056 -
Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care
|
Phase 1 | |
| Recruiting |
NCT04714814 -
Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
|
||
| Not yet recruiting |
NCT05451719 -
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
|
Phase 2 | |
| Completed |
NCT03031444 -
Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
|
Phase 2/Phase 3 | |
| Completed |
NCT05164419 -
Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
|
||
| Recruiting |
NCT05171660 -
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
|
Phase 3 |